Arbutus Biopharma Corporation (NASDAQ:ABUS) went up by 8.09% from its latest closing price compared to the recent 1-year high of $9.02. The company’s stock price has collected 10.94% of gains in the last five trading sessions. Press Release reported on 07/07/21 that Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
Is It Worth Investing in Arbutus Biopharma Corporation (NASDAQ :ABUS) Right Now?
Plus, the 36-month beta value for ABUS is at 2.89. Opinions of the stock are interesting as 4 analysts out of 6 who provided ratings for Arbutus Biopharma Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.92. ABUS currently public float of 77.39M and currently shorts hold a 6.98% ratio of that float. Today, the average trading volume of ABUS was 1.63M shares.
ABUS’s Market Performance
ABUS stocks went up by 10.94% for the week, with a monthly drop of -6.67% and a quarterly performance of -6.22%, while its annual performance rate touched 2.44%. The volatility ratio for the week stands at 6.15% while the volatility levels for the past 30 days are set at 6.04% for Arbutus Biopharma Corporation. The simple moving average for the period of the last 20 days is -0.96% for ABUS stocks with a simple moving average of -14.58% for the last 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Hold.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 25th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $10. The rating they have provided for ABUS stocks is “Buy” according to the report published on December 17th, 2020.
JMP Securities gave a rating of “Mkt Outperform” to ABUS, setting the target price at $8 in the report published on July 27th of the previous year.
ABUS Trading at -0.72% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.41% of loss for the given period.
Volatility was left at 6.04%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares sank -5.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.94% upper at present.
During the last 5 trading sessions, ABUS rose by +10.94%, which changed the moving average for the period of 200-days by -2.65% in comparison to the 20-day moving average, which settled at $2.96. In addition, Arbutus Biopharma Corporation saw -17.18% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ABUS starting from McElhaugh Michael J., who sale 20,000 shares at the price of $5.00 back on Feb 09. After this action, McElhaugh Michael J. now owns 1,307,457 shares of Arbutus Biopharma Corporation, valued at $100,000 using the latest closing price.
McElhaugh Michael J., the Chief Business Officer of Arbutus Biopharma Corporation, sale 40,000 shares at $5.00 during a trade that took place back on Dec 14, which means that McElhaugh Michael J. is holding 1,327,457 shares at $200,032 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -828.30 for the present operating margin
The net margin for Arbutus Biopharma Corporation stands at -921.97. The total capital return value is set at -52.16, while invested capital returns managed to touch -58.25. Equity return is now at value 147.90, with -61.40 for asset returns.
Based on Arbutus Biopharma Corporation (ABUS), the company’s capital structure generated 22.10 points at debt to equity in total, while total debt to capital is 18.10.
When we switch over and look at the enterprise to sales, we see a ratio of 45.98, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 5.50 and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.38.